D-1067-2019 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1067-2019 was initiated by Pfizer Inc. on Mar 15, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point The recall status is terminated (terminated Aug 11, 2022). Affected quantity: 67 cartons (25 vials per carton).

Recall details

Product Type
Drugs
Report Date
Apr 10, 2019
Initiation Date
Mar 15, 2019
Termination Date
Aug 11, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
67 cartons (25 vials per carton)

Product description

Cleocin Phosphate (clindamycin injection), USP, 300 mg/ 2 mL (150 mg/mL), 2 mL-vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017, NDC 0009-6582-02

Reason for recall

Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Distribution pattern

Nationwide USA and Guam

Code information

Lot #: T97469, Exp. 7/2019, W28574, Exp.09/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1067-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1067-2019. Report a data issue: hello@regdatalab.com.